37 related articles for article (PubMed ID: 38593446)
1. In vitro cytotoxic effect of a chitin-like polysaccharide produced by Mortierella alpina on adrenocortical carcinoma cells H295R, and its use as mitotane adjuvant.
Goyzueta Mamani LD; de Carvalho JC; Bonatto SJR; Tanobe VAO; Soccol CR
In Vitro Cell Dev Biol Anim; 2021 Apr; 57(4):395-403. PubMed ID: 33904018
[TBL] [Abstract][Full Text] [Related]
2. Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
Ohmoto A; Shigematsu Y; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Komai Y; Numao N; Yuasa T; Yonese J; Tomomatsu J; Inamura K; Takahashi S
Endocr J; 2021 Dec; 68(12):1383-1390. PubMed ID: 34176818
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
Abate A; Rossini E; Tamburello M; Laganà M; Cosentini D; Grisanti S; Fiorentini C; Tiberio GAM; Scatolini M; Grosso E; Hantel C; Memo M; Berruti A; Sigala S
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34875044
[TBL] [Abstract][Full Text] [Related]
4. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
[TBL] [Abstract][Full Text] [Related]
5. A Case of Drug Reaction With Eosinophilia and Systemic Symptoms Caused by Mitotane: A Cytotoxic Drug Treating Adrenocortical Carcinoma.
Qi J; Zhang Q; Jiang X
Dermatitis; 2024 Apr; ():. PubMed ID: 38593446
[No Abstract] [Full Text] [Related]
6. Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Corso CR; Acco A; Bach C; Bonatto SJR; de Figueiredo BC; de Souza LM
Br J Clin Pharmacol; 2021 Jul; 87(7):2698-2710. PubMed ID: 33382119
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Kroiss M; Quinkler M; Lutz WK; Allolio B; Fassnacht M
Clin Endocrinol (Oxf); 2011 Nov; 75(5):585-91. PubMed ID: 21883349
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive treatment of adrenocortical carcinoma.
Terzolo M; Berruti A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic chemotherapy for adrenocortical carcinoma.
Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic treatment of adrenocortical carcinoma.
Ahlman H; Khorram-Manesh A; Jansson S; Wängberg B; Nilsson O; Jacobsson CE; Lindstedt S
World J Surg; 2001 Jul; 25(7):927-33. PubMed ID: 11572034
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
